期刊文献+

FⅢ制作工艺优化对静注人免疫球蛋白(pH4)收率和关键质量指标的影响分析 被引量:2

Effect of FⅢ process optimization on the yield and key quality indexes of intravenous immunoglobulin
下载PDF
导出
摘要 目的优化静注人免疫球蛋白(pH4)FⅢ制作工艺参数,保证产品质量的同时,提高产品收率。方法将FⅡ+Ⅲ沉淀溶解后的乙酸钠、醋酸缓冲液和乙醇的加液时间分别由4 h、2 h、4 h延长为5 h、3 h、5 h;FⅡ+Ⅲ沉淀溶解温度由-0.5℃提高至1℃,FⅢ制作温度由-5.5℃提高至-5.0℃;对优化前后的人免疫球蛋白原液收率和关键质量指标(纯度、分子大小分布、抗补体活性、Fc生物学活性和激肽释放酶原激活剂)进行统计分析。结果加液时间延长和温度提高分别使人免疫球蛋白原液收率提高了19.6%和12.9%,且关键质量指标均未发生显著变化。结论 FⅢ制作过程加液时间和温度参数的优化,有效提高了人免疫球蛋白原液收率,未影响产品质量。 Objective To increase the yield of intravenous immunoglobulin by optimizing the FⅢ production process, under the premise of ensuring product quality. Methods The adding time of sodium acetate, acetic acid buffer and ethanol was adjusted from 4 h, 2 h and 4 h to 5 h, 3 h and 5 h, respectively. The temperature of FⅡ+Ⅲ precipitation dissolved was increased from-0.5℃ to 1℃, and FⅢ production temperature was increased from-5.5℃ to-5.0℃. The yield and key quality indexes(including purity, molecular size distribution, anti-complement activity, biological activity of Fc fragment and PKA) of human immunoglobulin concentrate before and after optimization were statistically analyzed. Results The yield of human immunoglobulin concentrate increased by 19.6% and 12.9%,respectively, with the prolongation of adding time and the increase of temperature, while the key quality indexes did not change significantly. Conclusion Optimizing parameters of solution adding time and temperature in FⅢ manufacturing process can effectively improve the yield of human immunoglobulin concentrate without affecting the key quality index.
作者 韩祥东 魏代锋 张杰 戈行 付俊德 刘晓 韩国德 张安山 郭广兆 HAN Xiangdong;WEI Daifeng;ZHAGN Jie;GE Xing;FU Junde;LIU Xiao;HAN Guode;ZHANG Anshan;GUO Guangzhao(Lanzhou Institute of Biological Product Co.,Ltd,Lanzhou 730046,China)
出处 《中国输血杂志》 CAS 2020年第2期155-157,共3页 Chinese Journal of Blood Transfusion
关键词 人免疫球蛋白 收率 纯度 分子大小分布 human immunoglobulin yield purity molecular size distribution
  • 相关文献

参考文献4

二级参考文献46

  • 1杨海荣,罗坚,董爱华,张计允,苏志国.疏水层析结合冷乙醇沉淀纯化人血清白蛋白[J].生物工程学报,2004,20(6):943-947. 被引量:8
  • 2肖林,程雅琴.人血白蛋白制品中铝含量的分析[J].中国生物制品学杂志,2005,18(6):528-530. 被引量:5
  • 3邱家山,黄晓军.人血浆蛋白连续沉淀分离技术试验[J].生物技术通讯,2006,17(5):762-763. 被引量:2
  • 4肖林.人血白蛋白制品铝残留量的追踪研究[J].药物分析杂志,2007,27(8):1218-1221. 被引量:5
  • 5国家药品监督管理局.血液制品去除/灭活病毒技术方法及验证指导原则[S].2002,国药监注[2002]160号
  • 6Wetzel R,Becker M,Behlke J,et al.Temperature behaviour of human serum albumin[J],Eur J Biochem,1980,104 (2):469-478
  • 7JensenLB,Dam J,Teisner B.Identification and removal of polymer-and aggregate-forming proteins in human plasma albumin preparations[J].Vox Sang,1994,67(2):125-131
  • 8MaruyamaT,Katoh S,Nakajima M,et al.Mechanism of bovine serum albumin aggregation during ultrafiltration[J].Biotechnol and Bioeng,2001,75(2) ;233-238
  • 9May JC,Rains TC,Yu LJ,et al.Aluminum content of source plasma and sodium citrate anticoagulant[J].Vox Sang,1992,
  • 10Debart PR,Torrecillas DC.Therapeutic human albumin having a low aluminum binding capacity[P],United States Patent; 5846930,1998-12-08

共引文献26

同被引文献18

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部